Stock Events

Stock Events

NovaBridge Biosciences. 

$4.63
64
-$0.01-0.22% Wednesday 19:59

Statistics

Day High
4.77
Day Low
4.49
52W High
6.79
52W Low
0.6
Volume
819,571
Avg. Volume
2,745,610
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

28AugExpected
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
-4.24
-2.83
-1.41
0
Expected EPS
N/A
Actual EPS
-0.28

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-15.48MNet Income

Analyst Ratings

$9.00Average Price Target
The highest estimate is 9.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow IMAB. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Zai Lab Limited
ZLAB
Mkt Cap2.91B
Zai Lab operates in the same therapeutic areas as I-Mab, including oncology and autoimmune diseases, making them direct competitors.
CytomX Therapeutics
CTMX
Mkt Cap588.74M
CytomX Therapeutics is involved in developing antibody therapeutics for cancer, similar to I-Mab's focus, positioning them as competitors.
Sana Biotechnology
SANA
Mkt Cap1.27B
Sana Biotechnology competes with I-Mab in the biotech space, focusing on engineering cells to create therapies that could overlap with I-Mab's work.
Novartis
NVS
Mkt Cap237.61B
Novartis is a large pharmaceutical company with a broad oncology portfolio, competing with I-Mab in cancer treatment research and development.
Merck
MRK
Mkt Cap214.76B
Merck is a global healthcare company with a strong emphasis on cancer treatments, directly competing with I-Mab's oncology focus.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol Myers Squibb has a significant presence in the oncology and immunoscience sectors, making it a competitor to I-Mab.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences has a diverse range of therapeutic products, including oncology and inflammatory diseases, areas where I-Mab is also active.
AMGEN
AMGN
Mkt Cap160.66B
Amgen focuses on human therapeutics, including oncology and hematology, which are key areas of focus for I-Mab.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals is involved in developing treatments for cancer and other diseases, competing with I-Mab in the biopharmaceutical field.

About

NovaBridge Biosciences, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell, and offer to sell FE301, an interleukin-6 inhibitor. The company also has collaborations with Bristol Myers Squibb for the development of givastomig; ABL Bio, Inc. for the development of givastomig and ragistomig; and TJ Bio for the development of uliledlimab. The company was formerly known as I-Mab and change its name to NovaBridge Biosciences in October 2025. NovaBridge Biosciences was founded in 2014 and is headquartered in Rockville, Maryland.
Show more...
CEO
Mr. Wei Fu
Employees
32
Country
KY
ISIN
US44975P1030

Listings

F
DE
0VY.F
XNAS
US
NBP
BOATS
BOATS
NBP.BOATS

0 Comments

Share your thoughts

FAQ

What is NovaBridge Biosciences. stock price today?▼
The current price of IMAB is $4.63 USD — it has decreased by -0.22% in the past 24 hours. Watch NovaBridge Biosciences. stock price performance more closely on the chart.
What is NovaBridge Biosciences. stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange NovaBridge Biosciences. stocks are traded under the ticker IMAB.
Is NovaBridge Biosciences. stock price growing?▼
IMAB stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year NovaBridge Biosciences. has showed a +487.71% increase.
What were NovaBridge Biosciences. earnings last quarter?▼
IMAB earnings for the last quarter are -0.28 USD per share, whereas the estimation was N/A USD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A USD per share.
What is NovaBridge Biosciences. revenue for the last year?▼
NovaBridge Biosciences. revenue for the last year amounts to 0 USD.
What is NovaBridge Biosciences. net income for the last year?▼
IMAB net income for the last year is -15.48M USD.
How many employees does NovaBridge Biosciences. have?▼
As of April 01, 2026, the company has 32 employees.
In which sector is NovaBridge Biosciences. located?▼
NovaBridge Biosciences. operates in the Health Care sector.
When did NovaBridge Biosciences. complete a stock split?▼
NovaBridge Biosciences. has not had any recent stock splits.
Where is NovaBridge Biosciences. headquartered?▼
NovaBridge Biosciences. is headquartered in Rockville, KY.